Combined FDG and NaF PET/CT study in patients (pts) with metastatic genitourinary tumors (mGU) treated with cabozantinib plus nivolumab plus /- ipilimumab (CaboNivo plus /-Ipi)

被引：0

作者：

Lin, Jeffrey

Mortazavi, Amir

Stein, Mark N.

Pal, Sumanta K.

Davarpanah, Nicole N.

Nadal, Rosa Maria

Francis, Deneise C.

Berniger, Marilise Anne

Monk, Paul

Kempf, Jeffrey

Becker, Murray

Sokol, Levi

McKinney, Yolanda

Knopp, Michael V.

Wright, Chadwick

Jung, Alex

Choyke, Peter L.

Mena, Esther

Lindenberg, Liza

Apolo, Andrea B.

机构：

[1] NIH, NCI, Genitourinary Malignancies Branch, Ctr Canc Res, Bethesda, MD USA

[2] Ohio State Univ, Arthur G James Canc Hosp, Wexner Med Ctr, Columbus, OH USA

[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[4] City Hope Natl Med Ctr, Comprehens Canc Ctr, Duarte, CA USA

[5] NIH, Bethesda, MD USA

[6] NCI, Leidos Biomed Inc, Bethesda, MD USA

[7] Ohio State Univ, Columbus, OH USA

[8] Rutgers Robert Wood Johnson Med Sch, Newark, NJ USA

[9] Mol Imaging Program, Ctr Canc Res, Bethesda, MD USA

[10] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA

[11] City Hope Natl Med Ctr, Duarte, CA USA

[12] NIH, NCI, Bethesda, MD USA

[13] NIH, NCI, Mol Imaging Program, Ctr Canc Res, Bethesda, MD USA

[14] NIH, Washington, DC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.e16017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16017

引用

页数：6

共 50 条

[31] Whole body bone metastases volume using F-18 NaF PET/CT predicts overall survival in urological malignancy patients treated with Cabozantinib plus Nivolumab alone or in combination th Ipilimumab
Lim, Ilhan
Lindenberg, Maria Liza
Mena, Esther
Verdini, Nicholas
Apolo, Andrea
Eary, Janet
Choyke, Peter
JOURNAL OF NUCLEAR MEDICINE, 2019, 60
[32] Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
Jain, R. K.
Chahoud, J.
Chatwal, M.
Kim, Y.
Dhillon, J.
Vosoughi, A.
Araujo, C.
Li, R.
Zhang, J.
Sonpavde, G. P.
ANNALS OF ONCOLOGY, 2021, 32 : S724 - S724
[33] Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience.
Alhalabi, Omar
Tannir, Nizar M.
Momin, Hassan Ahmed
Yilmaz, Bulent
Stephen, Bettzy
Ejezie, Chinenye Lynette
Moyers, Justin Tyler
Gurses, Serdar A.
How, Jeffrey
Fu, Siqing
Ahnert, Jordi Rodon
Hong, David S.
Piha-Paul, Sarina Anne
Subbiah, Vivek
Dumbrava, Ecaterina Elena
Karp, Daniel D.
Janku, Filip
Meric-Bernstam, Funda
Naing, Aung
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[34] A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.
Pili, Roberto
Adra, Nabil
Logan, Theodore F.
Burney, Heather
Atkins, Michael B.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[35] Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
Gul, Anita
Shah, Neil J.
Mantia, Charlene
Hammers, Hans J.
Ornstein, Moshe Chaim
McDermott, David F.
Atkins, Michael B.
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[36] CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Janjigian, Yelena Y.
Bendell, Johanna
Calvo, Emiliano
Kim, Joseph W.
Ascierto, Paolo A.
Sharma, Padmanee
Ott, Patrick A.
Peltola, Katriina
Jaeger, Dirk
Evans, Jeffry
de Braud, Filippo
Chau, Ian
Harbison, Christopher T.
Dorange, Cecile
Tschaika, Marina
Le, Dung T.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2836 - +
[37] Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib
Iacovelli, Roberto
Ciccarese, Chiara
Maruzzo, Marco
Atzori, Francesco
Galli, Luca
Scagliarini, Sarah
Massari, Francesco
Verzoni, Elena
Cannella, Antonella
Maratta, Maria Grazia
Caserta, Claudia
Bimbatti, Davide
Deppieri, Filippo Maria
Dessi, Mariele
Paolieri, Federico
Riccardi, Ferdinando
Bracarda, Sergio
De Giorgi, Ugo
Basso, Umberto
Tortora, Giampaolo
Procopio, Giuseppe
CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 498.e1 - 498.e9
[38] Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
Jain, Rohit K.
Yang, Yuanquan
Chadha, Juskaran
Zhang, Jingsong
Raymond, Sarah
Oschmann, Erika
Poehlman, Trey
Fan, Wenyi
Kim, Youngchul
Dhillon, Jasreman
Chahoud, Jad
Chatwal, Monica Sheila
Sonpavde, Guru P.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS713 - TPS713
[39] Phase 1 study to evaluate safety and efficacy of ipilimumab plus nivolumab plus external beam radiotherapy in patients with metastatic melanoma.
Postow, Michael Andrew
Knox, Susan Jane
McCabe, Danielle
Macri, Mary J.
Schwarzenberger, Paul
Ricciardi, Toni
Ryan, Aileen
Venhaus, Ralph Rudolph
Barker, Christopher Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[40] A multicenter phase II study of cabozantinib plus nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902)
Grilley-Olson, Juneko E.
Allred, Jacob B.
Schuetze, Scott
Davis, Elizabeth J.
Wagner, Michael J.
Poklepovic, Andrew Stewart
Waechter, Blake
Riedel, Richard F.
Welliver, Meng Xu
Berg, Stephanie A.
George, Suzanne
Robinson, Steven Ian
Googe, Paul B.
D'Angelo, Sandra P.
Schwartz, Gary K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →